This study was a prospective, observational, longitudinal patient survey of 698 adult patients prescribed DUPIXENT and enrolled in the patient support program.13,14
Surveys were completed at baseline (prior to DUPIXENT treatment) and at Months 1, 2, 3, 6, 9, 12, and 30-36 after initiation of DUPIXENT. Data are from an analysis of patients who had completed surveys through 1 month (n=631) and through 30-36 months (n=425). The use of concomitant prescription treatment categories was measured using the percentage of patients that required atopic dermatitis treatment categories (excluding DUPIXENT for Months 1 to 30-36); the recall period for use of atopic dermatitis therapies was during the past 4 weeks. Concomitant treatment categories were defined as prescription topicals (topical corticosteroid, topical calcineurin inhibitors), PDE4 inhibitors, systemic corticosteroids, systemic immunosuppressants, and phototherapy.13,14
Limitations of analysis:
The survey data were collected from patients who enrolled in the DUPIXENT patient support program, and these patients may have different characteristics and perspectives vs those who did not enroll. Patients who continue to respond to long-term surveys may be self-selecting for favorable effectiveness and safety. As observed data may bias results. Safety and tolerability data were not collected.14